Esperion Therapeutics, Inc. (0IIM.L)
USD 0.99
(4.32%)
USD 0.99
(4.32%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -155.56 Million USD | 13.34% |
| 2022 | -179.5 Million USD | 20.83% |
| 2021 | -226.73 Million USD | -86.77% |
| 2020 | -121.39 Million USD | -30.39% |
| 2019 | -93.1 Million USD | 54.49% |
| 2018 | -204.58 Million USD | -21.07% |
| 2017 | -168.98 Million USD | -121.91% |
| 2016 | -76.15 Million USD | -52.18% |
| 2015 | -50.04 Million USD | -38.14% |
| 2014 | -36.22 Million USD | -59.17% |
| 2013 | -22.75 Million USD | -123.04% |
| 2012 | -10.2 Million USD | -0.39% |
| 2011 | -10.16 Million USD | 0.0% |
| 2002 | -27.94 Million USD | -2.31% |
| 2001 | -27.31 Million USD | 0.93% |
| 2000 | -27.57 Million USD | -122.92% |
| 1999 | -12.36 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.57 Million USD | -96.43% |
| 2024 Q1 | 72.26 Million USD | 270.58% |
| 2023 FY | -155.56 Million USD | 13.34% |
| 2023 Q4 | -42.36 Million USD | -53.88% |
| 2023 Q2 | -37.05 Million USD | 23.76% |
| 2023 Q1 | -48.6 Million USD | -14.33% |
| 2023 Q3 | -27.53 Million USD | 25.7% |
| 2022 Q4 | -42.51 Million USD | -2.14% |
| 2022 Q3 | -41.62 Million USD | 20.53% |
| 2022 Q2 | -52.37 Million USD | -21.84% |
| 2022 Q1 | -42.98 Million USD | 22.72% |
| 2022 FY | -179.5 Million USD | 20.83% |
| 2021 Q4 | -55.62 Million USD | 0.21% |
| 2021 Q3 | -55.74 Million USD | -71.35% |
| 2021 FY | -226.73 Million USD | -86.77% |
| 2021 Q1 | -82.82 Million USD | 13.34% |
| 2021 Q2 | -32.53 Million USD | 60.72% |
| 2020 Q2 | 129.17 Million USD | 273.51% |
| 2020 FY | -121.39 Million USD | -30.39% |
| 2020 Q1 | -74.44 Million USD | -26.26% |
| 2020 Q3 | -80.55 Million USD | -162.36% |
| 2020 Q4 | -95.56 Million USD | -18.64% |
| 2019 Q4 | -58.96 Million USD | 10.35% |
| 2019 FY | -93.1 Million USD | 54.49% |
| 2019 Q1 | 86.92 Million USD | 243.33% |
| 2019 Q2 | -55.29 Million USD | -163.61% |
| 2019 Q3 | -65.76 Million USD | -18.93% |
| 2018 Q3 | -50.56 Million USD | -8.78% |
| 2018 Q4 | -60.64 Million USD | -19.95% |
| 2018 FY | -204.58 Million USD | -21.07% |
| 2018 Q1 | -46.89 Million USD | -21.19% |
| 2018 Q2 | -46.48 Million USD | 0.88% |
| 2017 Q2 | -43.66 Million USD | -6.78% |
| 2017 Q1 | -40.88 Million USD | -39.62% |
| 2017 Q3 | -45.73 Million USD | -4.76% |
| 2017 FY | -168.98 Million USD | -121.91% |
| 2017 Q4 | -38.69 Million USD | 15.39% |
| 2016 FY | -76.15 Million USD | -52.18% |
| 2016 Q2 | -14.33 Million USD | 3.31% |
| 2016 Q1 | -14.82 Million USD | -12.0% |
| 2016 Q3 | -17.71 Million USD | -23.59% |
| 2016 Q4 | -29.28 Million USD | -65.34% |
| 2015 Q3 | -12.91 Million USD | -3.67% |
| 2015 Q4 | -13.23 Million USD | -2.44% |
| 2015 Q1 | -11.42 Million USD | -21.8% |
| 2015 Q2 | -12.46 Million USD | -9.08% |
| 2015 FY | -50.04 Million USD | -38.14% |
| 2014 Q3 | -9.7 Million USD | -4.82% |
| 2014 Q4 | -9.38 Million USD | 3.3% |
| 2014 Q2 | -9.25 Million USD | -17.29% |
| 2014 Q1 | -7.89 Million USD | 18.96% |
| 2014 FY | -36.22 Million USD | -59.17% |
| 2013 Q2 | -4.27 Million USD | -27.75% |
| 2013 Q1 | -3.34 Million USD | -54.81% |
| 2013 Q4 | -9.73 Million USD | -80.07% |
| 2013 Q3 | -5.4 Million USD | -26.57% |
| 2013 FY | -22.75 Million USD | -123.04% |
| 2012 FY | -10.2 Million USD | -0.39% |
| 2012 Q3 | -2.99 Million USD | -4.41% |
| 2012 Q2 | -2.86 Million USD | -30.8% |
| 2012 Q1 | -2.18 Million USD | 0.0% |
| 2012 Q4 | -2.16 Million USD | 27.76% |
| 2011 FY | -10.16 Million USD | 0.0% |
| 2003 Q3 | -6.22 Million USD | 20.58% |
| 2003 Q2 | -7.83 Million USD | -10.5% |
| 2003 Q1 | -7.08 Million USD | -14.39% |
| 2002 FY | -27.94 Million USD | -2.31% |
| 2002 Q4 | -6.19 Million USD | 12.63% |
| 2002 Q3 | -7.09 Million USD | 2.92% |
| 2002 Q2 | -7.3 Million USD | 0.6% |
| 2002 Q1 | -7.35 Million USD | -10.51% |
| 2001 Q2 | -8.93 Million USD | 1.37% |
| 2001 Q1 | -9.06 Million USD | -57.64% |
| 2001 FY | -27.31 Million USD | 0.93% |
| 2001 Q4 | -6.65 Million USD | -2.21% |
| 2001 Q3 | -6.5 Million USD | 27.19% |
| 2000 Q2 | -7.68 Million USD | -30.63% |
| 2000 Q1 | -5.87 Million USD | 0.0% |
| 2000 Q4 | -5.74 Million USD | 30.45% |
| 2000 FY | -27.57 Million USD | -122.92% |
| 2000 Q3 | -8.26 Million USD | -7.6% |
| 1999 FY | -12.36 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 102.268% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 60.264% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 43.638% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -28.041% |
| uniQure N.V. | -282.87 Million USD | 45.006% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -111.668% |
| bluebird bio, Inc. | -244.26 Million USD | 36.313% |
| Imunon, Inc. | -21.03 Million USD | -639.704% |
| Dynavax Technologies Corporation | -37.02 Million USD | -320.123% |
| Editas Medicine, Inc. | -169.18 Million USD | 8.049% |
| Illumina, Inc. | -1.06 Billion USD | 85.448% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 66.223% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 107.869% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 114.307% |
| Myriad Genetics, Inc. | -123.7 Million USD | -25.758% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 162.002% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 41.916% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -2852.42% |
| Verastem, Inc. | -92.08 Million USD | -68.936% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.895% |
| Waters Corporation | 817.67 Million USD | 119.025% |
| Biogen Inc. | 1.29 Billion USD | 111.996% |
| Nektar Therapeutics | -137.42 Million USD | -13.198% |
| Perrigo Company plc | 151.9 Million USD | 202.411% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -245.103% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -40.635% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -248.273% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 180.005% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 43.226% |
| Evolus, Inc. | -49.23 Million USD | -215.973% |
| Adicet Bio, Inc. | -152.03 Million USD | -2.318% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -59.786% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 103.844% |
| FibroGen, Inc. | -281.81 Million USD | 44.8% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 111.523% |
| OPKO Health, Inc. | -157.02 Million USD | 0.929% |
| Homology Medicines, Inc. | -48.25 Million USD | -222.377% |
| Geron Corporation | -193.94 Million USD | 19.79% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 44.87% |
| Exelixis, Inc. | 170.88 Million USD | 191.034% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -54.287% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -179.007% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 69.811% |
| Zoetis Inc. | 3.06 Billion USD | 105.069% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 32.896% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -222.745% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 103.611% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -297.321% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 56.022% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 245.004% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 146.083% |
| Blueprint Medicines Corporation | -486.27 Million USD | 68.009% |
| Insmed Incorporated | -709.62 Million USD | 78.078% |
| TG Therapeutics, Inc. | 20.63 Million USD | 853.952% |
| Incyte Corporation | 620.52 Million USD | 125.07% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 78.584% |